Volume 29, Number 4—April 2023
CME ACTIVITY - Synopsis
Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004–2020
Table 2
Outcome | No. cases/total no. (%) |
---|---|
Died |
13/319 (4.1) |
Cure, complete outcome data | 258/306 (84.3) |
Cure, incomplete outcome data | 48/306 (15.6) |
Cure without sequelae | 197/258 (76.4) |
Cure with sequelae |
61/258 (23.6) |
Sequelae | |
Neurodevelopmental | 35/258 (13.6) |
Sensorineural hearing loss | 32/258 (12.4) |
Skin scarring | 16/258 (6.2) |
Loss of limbs or digits | 7/258 (2.7) |
Chronic kidney disease | 1/258 (0.4) |
Other sequelae* |
5/258 (1.9) |
Neurodevelopmental sequelae | |
Delayed development | 20/258 (7.8) |
Cerebral ischemia | 13/258 (5) |
Epilepsy | 8/258 (3.1) |
Learning, concentration, behavior, psychological | 8/258 (3.1) |
Other† | 10/258 (3.9) |
*Other: bone growth arrest 2/258 (0.8%); cardiomyopathy 1/258 (0.4%); gastrointestinal hemorrhage 1/258 (0.4%); panniculitis 1/258 (0.4%). †Other neurodevelopmental: chronic hydrocephalus 2/258 (0.8%); autism spectrum disorder 1/258 (0.4%); ataxia 1/258 (0.4%); carotid artery narrowing 1/258 (0.4%); chronic headache 1/258 (0·4%); cranial nerve palsy 1/258 (0.4%); encephalomalacia 1/258 (0.4%); hypertonia 1/258 (0.4%); syringomyelia 1/258 (0.4%).
Page created: February 01, 2023
Page updated: March 16, 2023
Page reviewed: March 16, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.